Evidence map›Paper›PMID 39429681›Full record

ArticleClinical Medicine Insights. Oncology2024

Utility of Circulating Tumor DNA Assay in Identifying Mutations and Guiding Matched Targeted Therapy in Lung Cancers.

Kun Li, Nana Zhang, Bing Xu, Zichen Liu, Dan Zhao, Yujie Dong, Jing Mu, Haifeng Lin, Guangyu Shan, Sihang Gao and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kun LiPathology Department, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Nana ZhangPathology Department, Beijing Chest Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0003-2023-3330
Bing XuDepartment of Bioinformatics, Beijing USCI Medical Devices Co., Ltd., Beijing, China.ORCID https://orcid.org/0000-0002-8968-2233
Zichen LiuPathology Department, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Dan ZhaoPathology Department, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Yujie DongPathology Department, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Jing MuPathology Department, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Haifeng LinPathology Department, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Guangyu ShanDepartment of Bioinformatics, Beijing USCI Medical Devices Co., Ltd., Beijing, China.
Sihang GaoDepartment of Bioinformatics, Beijing USCI Medical Devices Co., Ltd., Beijing, China.
Bo YuDepartment of Bioinformatics, Beijing USCI Medical Devices Co., Ltd., Beijing, China.
Xiaoxi PanDepartment of Bioinformatics, Beijing USCI Medical Devices Co., Ltd., Beijing, China.
Yanrong WangDepartment of Bioinformatics, Beijing USCI Medical Devices Co., Ltd., Beijing, China.
Dongxing ZhangDepartment of Bioinformatics, Beijing USCI Medical Devices Co., Ltd., Beijing, China.
Nanying ChePathology Department, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Xiaoyong JiDepartment of Bioinformatics, Beijing USCI Medical Devices Co., Ltd., Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tumor genomic profiling has a significant impact on the selection of targeted therapy. Circulating tumor DNA (ctDNA) has emerged as a noninvasive, and reproducible assay compared with tissue biopsy. We aimed to evaluate its utility in identifying mutations and guiding targeted therapy for lung cancer. Methods: A total of 173 lung cancer patients underwent next-generation sequencing (NGS) using a targeted enrichment panel covering 20 lung cancer-related genes. The performance of the ctDNA NGS assay in identifying genetic mutations or alterations was compared with tissue biopsy and droplet digital PCR (ddPCR). The treatment response to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapies based on the ctDNA assay results was also assessed. Results: The ctDNA was detected in 61.85% of patients. Tissue mutations were detected in paired ctDNA in 38.57% of cases, while ctDNA mutations were detected in paired tissues in 89.1% of cases. The ctDNA increased the number of advanced non-small cell lung cancer (NSCLC) patients who received NCCN-recommended genetic testing by 12%. The concordance between ddPCR and ctDNA was relatively high reaching 99.43%. Conclusions: The results demonstrated that the ctDNA assay could partially overcome tumor heterogeneity in detecting mutations and provide complementary information on tumor genomic profiles. Moreover, the presence of

Indexed as

Circulating tumor DNAliquid biopsylung cancertumor biopsytumor heterogeneity

Identifiers

PMID39429681
PMCPMC11489900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.